Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. With five approved products, including ONPATTRO and AMVUTTRA, Alnylam targets rare diseases like hereditary transthyretin-mediated amyloidosis. The company aims to expand its pipeline with over 20 clinical programs, focusing on high unmet medical needs. Alnylam's strategic initiatives, including collaborations with Roche and Novartis, support its goal of becoming a top-tier biotech by 2025.
This description was generated via AI from an annual report. Updated about 1 year ago.